1
|
Wang H, Feng J, Liu Y, Qian Z, Gao D, Ran X, Zhou H, Liu L, Wang B, Fang M, Zhou H, Huang Z, Tao S, Chen Z, Su L, Su H, Yang Y, Xie X, Wu H, Sun P, Hu G, Liang A, Li Z. Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma. Signal Transduct Target Ther 2024; 9:99. [PMID: 38627366 PMCID: PMC11021411 DOI: 10.1038/s41392-024-01798-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2023] [Revised: 03/06/2024] [Accepted: 03/10/2024] [Indexed: 04/19/2024] Open
Abstract
This registration study assessed clinical outcomes of TQ-B3525, the dual phosphatidylinositol-3-kinase (PI3K) α/δ inhibitor, in relapsed and/or refractory follicular lymphoma (R/R FL). This phase II study (ClinicalTrials.gov NCT04324879. Registered March 27, 2020) comprised run-in stage and stage 2. R/R FL patients after ≥2 lines therapies received oral 20 mg TQ-B3525 once daily in a 28-day cycle until intolerable toxicity or disease progression. Primary endpoint was independent review committee (IRC)-assessed objective response rate (ORR). Based on results (ORR, 88.0%; duration of response [DOR], 11.8 months; progression-free survival [PFS], 12.0 months) in 25 patients at run-in stage, second stage study was initiated and included 82 patients for efficacy/safety analysis. Patients received prior-line (median, 3) therapies, with 56.1% refractory to previous last therapies; 73.2% experienced POD24 at baseline. At stage 2, ORR was 86.6% (71/82; 95% CI, 77.3-93.1%), with 28 (34.2%) complete responses. Disease control rate was 95.1% due to 7 (8.5%) stable diseases. Median time to response was 1.8 months. Among 71 responders, median DOR was not reached; 18-month DOR rate was 51.6%. with median follow-up of 13.3 months, median PFS was 18.5 (95% CI, 10.2-not estimable) months. Median overall survival (OS) was not reached by cutoff date; 24-month OS rate was estimated as 86.1%. Response rates and survival data were consistent across all subgroups. Grade 3 or higher treatment-related adverse events were observed in 63 (76.8%) cases, with neutropenia (22.0%), hyperglycemia (19.5%), and diarrhea (13.4%) being common. TQ-B3525 showed favorable efficacy and safety for R/R FL patients after ≥2 lines prior therapies.
Collapse
Affiliation(s)
- Huaqing Wang
- Department of Oncology, Tianjin Union Medical Center of Nankai University, Tianjin, 300121, PR China
- The Institute of Translational Medicine, Tianjin Union Medical Center of Nankai University, Tianjin, 300121, PR China
| | - Jifeng Feng
- Department of Medical Oncology, Jiangsu Cancer Hospital, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, PR China
| | - Yanyan Liu
- Department of Medical Oncology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450003, PR China
| | - Zhengzi Qian
- Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, PR China
| | - Da Gao
- Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical College, 010050, Hohhot, PR China
| | - Xuehong Ran
- Department of Hematology, Weifang People's Hospital, The First Affiliated Hospital of Weifang Medical University, 261000, Weifang, PR China
| | - Hui Zhou
- Department of Lymphoma & Hematology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013, Changsha, PR China
| | - Lihong Liu
- Department of Hematology, The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, 050011, Shijiazhuang, PR China
| | - Binghua Wang
- Department of Lymphoma, Weihai Central Hospital, 264400, Weihai, PR China
| | - Meiyun Fang
- Department of Hematology and Rheumatology, The Affiliated Zhongshan Hospital of Dalian University, 116001, Dalian, PR China
| | - Hebing Zhou
- Department of Hematology, Beijing Luhe Hospital, 101199, Beijing, PR China
| | - Zhenqian Huang
- Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, 510120, Guangzhou, PR China
| | - Shi Tao
- Department of Hematology, The First Affiliated Hospital of Hainan Medical College, 570102, Haikou, PR China
| | - Zhuowen Chen
- Department of Hematology, The First People's Hospital of Foshan, 528000, Foshan, PR China
| | - Liping Su
- Department of Hematology, Shanxi Cancer Hospital, 030013, Taiyuan, PR China
| | - Hang Su
- Department of Lymphoma, Senior Department of Hematology, The Fifth Medical Center of Chinese PLA General Hospital, 100039, Beijing, PR China
| | - Yu Yang
- Department of Lymphoma and Head and Neck Cancer, Fujian Cancer Hospital, 350014, Fuzhou, PR China
| | - Xiaobao Xie
- Department of Hematology, The First People's Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, 213003, Changzhou, PR China
| | - Huijing Wu
- Department of Medical Oncology, Hubei Cancer Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, 430079, Wuhan, PR China
| | - Ping Sun
- Department of Medical Oncology, Yantai Yuhuangding Hospital, 264000, Yantai, PR China
| | - Guoyu Hu
- Department of Hematology, Zhuzhou Central Hospital, 412007, Zhuzhou, PR China
| | - Aibin Liang
- Department of Hematology, Tongji Hospital of Tongji University, Shanghai, 200333, PR China.
| | - Zhiming Li
- Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 510060, Guangzhou, PR China.
| |
Collapse
|
2
|
Zhou H, Wang Y, Chen J, He A, Jin J, Lu Q, Zhao Y, Li J, Hou M, Su L, Lai X, Wang W, Liu L, Ma Y, Gao D, Lai W, Zhou X, Jing H, Zhang J, Yang W, Ran X, Lin C, Hao J, Xiao T, Huang Z, Zhu Z, Wang Q, Fang B, Wang B, Song Y, Cai Z, Liu B, Zhu Y, Yang X, Kang X, Li J, Chen W. Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial. Ann Hematol 2024; 103:855-868. [PMID: 38112795 PMCID: PMC10866745 DOI: 10.1007/s00277-023-05558-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Accepted: 11/18/2023] [Indexed: 12/21/2023]
Abstract
This multicenter, open-label, single-arm trial (ClinicalTrials.gov, NCT05236621) was conducted to confirm the efficacy and safety of generic pomalidomide plus dexamethasone in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Total 79 eligible RRMM patients were planned to be included. Patients were treated with generic pomalidomide (4 mg daily on days 1-21, orally) and low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally; 20 mg for patients aged > 75 years) in 28-day cycles until disease progression with a maximum treatment duration of 2 years. The primary endpoint is the overall response rate (ORR) assessed by the independent review committee per the 2016 International Myeloma Working Group guidelines. A total of 85 eligible patients were included in this study from 32 centers in China, with a median age of 62.0 (range, 39-76) years, a median prior line of therapy of 4 (range, 1-16), and 41.2% patients with high-risk cytogenetics. The ORR was 38.8% (95% confidence interval (CI), 28.44-50.01). The disease control rate was 67.1% (95% CI, 56.02-76.87), meanwhile, the median progression-free survival was 5.55 months (95% CI, 3.68-7.52). Among the treatment-related adverse events (TRAEs), infective pneumonia (17.6%) was the most frequent non-hematologic adverse event, while a decrease in neutrophil count (52.9%) was the most common grade ≥ 3 TRAE. The study results indicated that the generic pomalidomide demonstrated consistent efficacy and a safety profile similar to the branded pomalidomide when combined with low-dose dexamethasone in Chinese RRMM patients.Registration number ClinicalTrials.gov NCT05236621, retrospectively registered on February 11, 2022.
Collapse
Affiliation(s)
- Huixing Zhou
- Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, #8, the South Road of Workers Stadium of Chaoyang District, Beijing, 100020, China
| | - Yafei Wang
- Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Jiao Chen
- Department of Hematology, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, Chengdu, China
| | - Aili He
- Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Jie Jin
- Department of Hematology, The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China
| | - Quanyi Lu
- Department of Hematology, Zhongshan Hospital Affiliated to Xiamen University, Xiamen, China
| | - Ying Zhao
- Department of Hematology, The First People's Hospital of Foshan, Guangzhou, China
| | - Junjun Li
- Department of Hematology, The First Affiliated Hospital of University of South China, Hengyang, China
| | - Ming Hou
- Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
| | - Liping Su
- Department of Hematology, Shanxi Provincial Cancer Hospital, Taiyuan, China
| | - Xun Lai
- Department of Hematology, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Center, Kunming, China
| | - Wei Wang
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao, China
| | - Lihong Liu
- Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Yanping Ma
- Department of Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China
| | - Da Gao
- Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China
| | - Wenhong Lai
- Department of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China
| | - Xin Zhou
- Department of Hematology, Wuxi People's Hospital, Wuxi, China
| | - Hongmei Jing
- Department of Hematology, Peking University Third Hospital, Beijing, China
| | - Jinqiao Zhang
- Department of Hematology, The Third Hospital of Hebei Medical University, Shijiazhuang, China
| | - Wei Yang
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China
| | - Xuehong Ran
- Department of Hematology, Weifang People's Hospital, Weifang, China
| | - Congmeng Lin
- Department of Hematology, Zhangzhou Municicap Hospital of Fujian Province, Zhangzhou, China
| | - Jianping Hao
- Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumchi, China
| | - Taiwu Xiao
- Department of Hematology, Liaocheng People's Hospital, Liaocheng, China
| | - Zhenqian Huang
- Department of Hematology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
| | - Zhigang Zhu
- Department of Geriatric Hematologic Oncology, Guangzhou First People's Hospital, Guangzhou, China
| | - Qing Wang
- Department of Hematopathology, Guizhou Provincial People's Hospital, Guiyang, China
| | - Baijun Fang
- Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhenghzou University, Zhengzhou, China
| | - Binghua Wang
- Department of Hemolymph, Weihai Central Hospital, Weihai, China
| | - Yanping Song
- Department of Hematology, Xi'an Central Hospital, Xi'an, China
| | - Zhen Cai
- Bone Marrow Transplantation Center, the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
| | - Bo Liu
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China
| | - Yanan Zhu
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China
| | - Xinai Yang
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China
| | - Xiaoyan Kang
- Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, China
| | - Juan Li
- Department of Hematology, First Affiliated Hospital of Sun Yat-Sen University, #58, The 2nd Zhongshan Road, Yuexiu District, Guangzhou, 510062, China.
| | - Wenming Chen
- Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, #8, the South Road of Workers Stadium of Chaoyang District, Beijing, 100020, China.
| |
Collapse
|
3
|
Zhou H, Han S, Jin J, Huang R, Guo X, Shen X, Wang B, Wang X, Yao H, Du X, Huang M, Ran X, Wang W, Yang T, Zhang F, Zheng C, Zuo X, Fu R, Gao D, Ge Z, Han Y, Li Y, Kang X, Shi Y, Hou M. Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial. J Transl Int Med 2023; 11:423-432. [PMID: 38130645 PMCID: PMC10732573 DOI: 10.2478/jtim-2023-0106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2023] Open
Abstract
Objective QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein, is a romiplostim (Nplate®) biosimilar used to treat primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with chronic primary ITP over a 24-week treatment period. Methods We conducted a double-blind, placebo-controlled, phase III study in patients diagnosed with primary ITP for at least 12 months who had received at least one first-line ITP treatment with no response or recurrence after treatment, or who relapsed after splenectomy at 44 sites in China. Patients were randomly allocated (2:1 ratio) to QL0911 or placebo injection subcutaneously once weekly at an initial dose of 1 μg/kg for 24 weeks. The doses were adjusted to maintain the target platelet counts from 50 × 109/L to 200 × 109/L. Patients and investigators were blinded to the assignment. The primary endpoints were the proportion of patients who achieved a durable platelet response at week 24 (platelet count, ≥ 50 × 109/L during 6 of the last 8 weeks of treatment) and safety. The study was registered at ClinicalTrials.gov (NCT05621330). Results Between October 2019 and December 2021, 216 patients were randomly assigned (QL0911,144; placebo,72). A durable platelet response was achieved by significantly more patients in the QL0911 group (61.8%, 95% CI: 53.3-69.8; P < 0.0001) than in the placebo group (0%). The mean duration of platelet responses was 15.9 (SE: 0.43) weeks with QL0911, and 1.9 (SE:0.26) week with placebo. Consistent results were achieved in subgroup analyses categorized by baseline splenectomy status (yes/no), concomitant ITP treatment (yes/no), and baseline platelet count (≤ 10 × 109/L, > 10 × 109/L, ≤ 20 × 109/L, > 20 × 109/L, and < 30 × 109/L). The incidence of TEAEs was comparable between the QL0911 and the placebo groups (91.7% and 88.9%, respectively). The most common adverse events overall were ecchymosis (28.5% for QL0911 vs. 37.5% for placebo), upper respiratory tract infections respiratory tract infections (31.9% for QL0911 vs. 27.8% for placebo), and gingival bleeding (17.4% for QL0911 vs. 26.4% for placebo). Conclusion QL0911 was well-tolerated and increased and maintained platelet counts in adults with ITP. QL0911, a biosimilar to romiplostim (Nplate®), may be a novel treatment option for patients with ITP who have failed or relapsed from first-line treatment in China. Ongoing studies will provide further data on long-term efficacy and safety in such patient populations.
Collapse
Affiliation(s)
- Hu Zhou
- Department of Hematology, Henan Cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou450008, Henan Province, China
| | - Shouqing Han
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan250012, Shandong Province, China
| | - Jie Jin
- Department of Hematology, The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 310003, Zhejiang Province, China
| | - Ruibin Huang
- Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang330006, Jiangxi Province, China
| | - Xinhong Guo
- Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi830054, Xinjiang Uygur Autonomous Region, China
| | - Xuliang Shen
- Department of Hematology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi046000, Shanxi Province, China
| | - Binghua Wang
- Department of Hematology, Weihai Central Hospital, Weihai264400, Shandong Province, China
| | - Xin Wang
- Department of Hematology, Suining Central Hospital, Suining629099, Sichuan Province, China
| | - Hongxia Yao
- Department of Hematology, Hainan General Hospital, Haikou570311, Hainan Province, China
| | - Xin Du
- Department of Hematology, Shenzhen Second People’s Hospital, Shenzhen518035, Guangdong Province, China
| | - Meijuan Huang
- Department of Hematology, Fujian Medical University Union Hospital, Fuzhou350001, Fujian Province, China
| | - Xuehong Ran
- Department of Hematology, Weifang People’s Hospital, Weifang261044, Shandong Province, China
| | - Wei Wang
- Department of Hematology, The Affiliated Hospital of Qingdao University, Qingdao266000Qingdao, Shandong Province, China
| | - Tonghua Yang
- Department of Hematology, The First People’s Hospital of Yunnan Province, Kunming650031, Yunnan Province, China
| | - Feng Zhang
- Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu233004, Anhui Province, China
| | - Changcheng Zheng
- Department of Hematology, Anhui Province Hospital, Hefei230002, Anhui Province, China
| | - Xuelan Zuo
- Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan430071, Hubei Province, China
| | - Rong Fu
- Department of Hematology, Tianjin Medical University General Hospital, Tianjin300052, China
| | - Da Gao
- Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Tongliao028000, Inner Mongolia, China
| | - Zheng Ge
- Department of Hematology, Zhongda Hospital Southeast University, Nanjing210009, Jiangsu Province, China
| | - Ying Han
- Department of Medicine, Qilu Pharmaceutical Co., Ltd, Jinan250100, Shandong Province, China
| | - Yujie Li
- Statistics and Statistical Programming, Qilu Pharmaceutical Co., Ltd, Jinan250100, Shandong Province, China
| | - Xiaoyan Kang
- Department of Medicine, Qilu Pharmaceutical Co., Ltd, Jinan250100, Shandong Province, China
| | - Yan Shi
- Department of Hematology, Qilu Hospital of Shandong University, Jinan250012, Shandong Province, China
| | - Ming Hou
- Department of Hematology, Qilu Hospital of Shandong University, Jinan250012, Shandong Province, China
- Department of Hematology, Shandong Provincial Key Laboratory of Immunohematology, Qilu Hospital of Shandong University, Jinan250012, Shandong Province, China
| |
Collapse
|
4
|
Wu M, Wang F, Zhao S, Li Y, Huang W, Nie B, Liu H, Liu X, Li W, Yu H, Yi K, Dong F, Dong Y, Yuan C, Ran X, Xiao X, Liu W, Zhu J. Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study. Ann Hematol 2023; 102:3185-3193. [PMID: 37700194 PMCID: PMC10567887 DOI: 10.1007/s00277-023-05416-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2023] [Accepted: 08/10/2023] [Indexed: 09/14/2023]
Abstract
The aim of this study is to evaluate the survival benefit of consolidative autologous hematopoietic stem cell transplantation (ASCT) in patients with peripheral T-cell lymphomas (PTCL). In this retrospective study, the ASCT group underwent consolidative ASCT after first-line therapy at 14 transplantation centers in China between January 2001 and December 2019. Data were collected over the same time frame for the non-ASCT group from the database of lymphoma patient records at Peking University Cancer Hospital & Institute. A total of 120 and 317 patients were enrolled in the ASCT and non-ASCT groups, respectively, and their median ages were 43 years and 51 years, respectively. In the ASCT group, 101 patients had achieved complete remission (CR) and 19 patients had achieved partial remission at the time of ASCT. The median follow-up time was 40.2 months and 68 months, and the 3-year overall survival (OS) rate was 80.6% and 48.9% (p < 0.001) for the ASCT and non-ASCT groups, respectively. The beneficial effect of ASCT for OS remained even after propensity score-matched (PSM) analysis (81.6% vs 68.3%, p = 0.001). Among the 203 patients who were aged ≤ 65 years and achieved CR, ASCT conferred a significant survival benefit (3-year progression-free survival [PFS]: 67.4% vs 47.0%, p = 0.004; 3-year OS: 84.0% vs 74.1%, p = 0.010), and this was also maintained after PSM analysis (3-year PFS: 66.6% vs 48.4%, p = 0.042; 3-year OS: 84.8% vs 70.5%, p = 0.011). Consolidative ASCT improved the survival outcome of PTCL patients, even those who achieved CR after first-line therapy.
Collapse
Affiliation(s)
- Meng Wu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China
| | - Fengrong Wang
- Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People's Hospital & Institute of Hematology, Beijing, China
| | - Shihua Zhao
- Department of Lymphoma and Plasmacytoma Disease, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing, China
| | - Yajun Li
- Department of Lymphoma and Hematology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
| | - Wenrong Huang
- Department of Lymphoma and Plasmacytoma Disease, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing, China
| | - Bo Nie
- Department of Hematology, the First Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Haisheng Liu
- Department of Hematology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Xiaoqian Liu
- Department of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, Shandong, China
| | - Wei Li
- Department of Lymphoma, Key Laboratory of Cancer Prevention and Therapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin, China
| | - Haifeng Yu
- Department of Lymphatic Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China
| | - Kun Yi
- Department of Lymphoma and Hematology, Jiangxi Cancer Hospital of Nanchang University, Nanchang, China
| | - Fei Dong
- Department of Hematology, Peking University 3Rd Hospital, Beijing, China
| | - Yujun Dong
- Department Hematology, Peking University First Hospital, Beijing, China
| | - Chenglu Yuan
- Department of Hematology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China
| | - Xuehong Ran
- Hematology Department, Weifang People's Hospital, Weifang, China
| | - Xiubin Xiao
- Department of Lymphoma and Plasmacytoma Disease, Senior Department of Hematology, the Fifth Medical Center of PLA General Hospital, Beijing, China
| | - Weiping Liu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
| | - Jun Zhu
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
| |
Collapse
|
5
|
Wu HY, Zhou X, Chu XX, Deng XZ, Yuan CL, Ran XH, Liu GQ, Fan CB, Hao HY, Zhong YP. [Bendamustine combined with pomalidomide and dexamethasone in relapsed multiple myeloma with extramedullary disease: a multicenter study]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:667-671. [PMID: 37803841 PMCID: PMC10520229 DOI: 10.3760/cma.j.issn.0253-2727.2023.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Indexed: 10/08/2023]
Abstract
Objective: To evaluate the efficacy and safety of bendamustine combined with pomalidomide and dexamethasone (BPD regimen) in the treatment of relapsed multiple myeloma (MM) with extramedullary disease. Methods: This open, single-arm, multicenter prospective cohort study included 30 relapsed MM patients with extramedullary disease diagnosed in seven hospitals including Qingdao Municipal Hospital. The patients were treated with BPD regimen from February 2021 to November 2022. This study analyzed the efficacy and adverse reactions of the BPD regimen. Results: The median age of the 30 patients was 62 (47-72) years, of which 18 (60% ) had first-time recurrence. The overall response rate (ORR) of the 18 patients with first-time recurrence was 100%, of which three (16.7% ) achieved complete remission, 10 (55.5% ) achieved very good partial remission (VGPR), and five (27.8% ) achieved partial remission (PR). The ORR of 12 patients with recurrence after second-line or above treatment was 50%, including zero patients with ≥VGPR and six patients (50% ) with PR. Three cases (25% ) had stable disease, and three cases (25% ) had disease progression. The one-year progression free survival rate of all patients was 65.2% (95% CI 37.2% -83.1% ), and the 1-year overall survival rate was 90.0% (95% CI 76.2% -95.4% ). The common grade 3-4 hematology adverse reactions included two cases (6.7% ) of neutropenia and one case (3.3% ) of thrombocytopenia. The overall adverse reactions are controllable. Conclusions: The BPD regimen has good efficacy and tolerance in relapsed MM patients with extramedullary disease.
Collapse
Affiliation(s)
- H Y Wu
- Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao 266071, China
| | - X Zhou
- Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao 266071, China
| | - X X Chu
- Yantai Yuhuangding Hospital, Yantai 264099, China
| | - X Z Deng
- Weihai Municipal Hospital, Weihai 264299, China
| | - C L Yuan
- Qilu Hospital of Shandong University, Qingdao 266035, China
| | - X H Ran
- Weifang People's Hospital, Weifang 261044, China
| | - G Q Liu
- Shengli Oilfield Center Hospital, Dongying 257099, China
| | - C B Fan
- Qingdao Haici Medical Group, Qingdao 266033, China
| | - H Y Hao
- Qilu Hospital of Shandong University, Qingdao 266035, China
| | - Y P Zhong
- Qingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao 266071, China
| |
Collapse
|
6
|
Wu XF, Li CC, Li TT, Sun L, Lu J, Ran XH. [Efficacy and safety of dexcitabine combined with HAAG regimen in the treatment of recurrent acute myeloid leukemia]. Zhonghua Yi Xue Za Zhi 2023; 103:981-985. [PMID: 36990713 DOI: 10.3760/cma.j.cn112137-20220712-01540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 03/31/2023]
Abstract
Objective: To investigate the efficacy and safety of dexithabine (DAC) combined with HAAG regimen [harringtonine (HHT), cytarabine (Ara-C), aclarubicin (Acla) and recombinant human granulocyte colony stimulating factor (G-CSF)] in the treatment of acute myeloid leukemia (AML). Methods: The clinical data of 89 AML patients in People's Hospital Affiliated to Shandong First Medical University from January 2019 to January 2021 were retrospectively analyzed. The patients were divided into observation group (n=48) and control group (n=41) according to the treatment plan. The observation group included 25 males and 23 females, aged (44.4±9.3) years old, and was treated with DAC combined with HAAG. The control group included 24 males and 17 females, aged (42.2±10.1) years old, and was treated with DAC regimen. After 3 cycles of treatment, the treatment efficacy of the two groups was judged, including complete remission, partial remission and no remission. The level of serum P-glycoprotein (P-gp) in the two groups was detected by direct immunofluorescence-labeled monoclonal antibody flow cytometry. The enzyme-linked immunosorbent assay was used to detect the level of soluble urokinase-type plasminogen activator receptor (suPAR). Meanwhile, the incidence of adverse reactions such as digestive tract reaction, liver and kidney dysfunction, hemorrhage and infection during treatment were recorded. Results: After 3 cycles of treatment, the observation group had complete remission, partial remission and no remission in 10 cases, 21 cases and 17 cases, respectively, and the control group had 3 cases, 11 cases and 27 cases, respectively. The overall efficacy of the observation group was better than that of the control group (Z=-2.919, P=0.004). The levels of serum P-gp and suPAR in the observation group were (5.2±1.8) % and (464.4±103.4) ng/L, respectively, which were significantly lower than those in the control group [(8.8±1.9) % and (660.6±110.4) ng/L, respectively] (both P<0.05). During the treatment, the incidence of digestive tract reaction, liver and kidney dysfunction, hemorrhage and infection in the observation group was 29.2% (14/48), 22.9% (11/48), 16.7% (8/48) and 33.3% (16/48), respectively, while in the control group was 26.8% (11/41), 21.9% (9/41), 14.6% (6/41) and 24.4% (10/41), respectively, with no statistically significant difference (all P>0.05). Conclusions: The overall efficacy of DAC combined with HAAG in the treatment of AML is better than that of DAC alone. Moreover, the incidence of adverse reactions in DAC combined with HAAG is similar to that of DAC alone, with a high safety profile.
Collapse
Affiliation(s)
- X F Wu
- Department of Hematology, People's Hospital Affiliated to Shandong First Medical University, Jinan 271199, China
| | - C C Li
- Department of Hematology, People's Hospital Affiliated to Shandong First Medical University, Jinan 271199, China
| | - T T Li
- Department of Hematology, People's Hospital Affiliated to Shandong First Medical University, Jinan 271199, China
| | - L Sun
- Department of Hematology, People's Hospital Affiliated to Shandong First Medical University, Jinan 271199, China
| | - J Lu
- Department of Hematology, People's Hospital Affiliated to Shandong First Medical University, Jinan 271199, China
| | - X H Ran
- Department of Hematology, Weifang People's Hospital of Shandong Province, Weifang 261042, China
| |
Collapse
|
7
|
Zheng S, Hao H, Tang Y, Ran X. High-purity orbital angular momentum vortex beam generator using an amplitude-and-phase metasurface. Opt Lett 2021; 46:5790-5793. [PMID: 34851891 DOI: 10.1364/ol.441426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Accepted: 10/04/2021] [Indexed: 06/13/2023]
Abstract
In this Letter, we propose an approach to generate high-purity orbital angular momentum (OAM) vortex waves using an amplitude-and-phase metasurface (APM). By varying the square split ring opening and orientation angles, the cross-polarized reflection response of the proposed structure can yield full phase and amplitude coverage. Based on the traditional phase-only metasurface (POM), the Chebyshev synthesis method (CSM) is applied to array the metasurface amplitude distribution. Metasurfaces with modes l of 1, 2, 3, and 4 are designed. Compared with the POM, the APM can effectively improve the vortex beam quality and OAM mode purity. The measured results agree well with full-wave simulations. The presented method provides a new, to the best of our knowledge, way to design high-purity OAM generators based on metasurfaces.
Collapse
|
8
|
Yu Y, Wang M, Hou Y, Qin P, Zeng Q, Yu W, Guo X, Wang J, Wang X, Liu G, Chu X, Yang L, Feng Y, Zhou F, Sun Z, Zhang M, Wang X, Wang Z, Ran X, Zhao H, Wang L, Zhang H, Bi K, Li D, Yuan C, Xu R, Wang Y, Zhou Y, Peng J, Liu X, Hou M. High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial. Am J Hematol 2020; 95:1542-1552. [PMID: 32871029 DOI: 10.1002/ajh.25989] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Revised: 08/19/2020] [Accepted: 08/29/2020] [Indexed: 12/24/2022]
Abstract
We conducted a prospective, multicenter, randomized, controlled clinical trial to compare the efficacy and safety of high-dose dexamethasone (HD-DXM) plus recombinant human thrombopoietin (rhTPO), vs HD-DXM alone in newly diagnosed adult immune thrombocytopenia (ITP) patients. Enrolled patients were randomly assigned to receive DXM plus rhTPO or DXM monotherapy. Another 4-day course of DXM was repeated if response was not achieved by day 10 in both arms. One hundred patients in the HD-DXM plus rhTPO arm and 96 patients in the HD-DXM monotherapy arm were included in the full analysis set. So, HD-DXM plus rhTPO resulted in a higher incidence of initial response (89.0% vs 66.7%, P < .001) and complete response (CR, 75.0% vs 42.7%, P < .001) compared with HD-DXM monotherapy. Response rate at 6 months was also higher in the HD-DXM plus rhTPO arm than that in the HD-DXM monotherapy arm (51.0% vs 36.5%, P = .02; sustained CR: 46.0% vs 32.3%, P = .043). Throughout the follow-up period, the overall duration of response was greater in the HD-DXM plus rhTPO arm compared to the HD-DXM monotherapy arm (P = .04), as estimated by the Kaplan-Meier analysis. The study drugs were generally well tolerated. In conclusion, the combination of HD-DXM with rhTPO significantly improved the initial response and yielded favorable SR in newly diagnosed ITP patients, thus could be further validated as a frontline treatment for ITP. This study is registered as clinicaltrials.gov identifier: NCT01734044.
Collapse
Affiliation(s)
- Yafei Yu
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine Shandong University Jinan Shandong China
| | - Miaomiao Wang
- Department of Pediatrics The Second Hospital, Cheeloo College of Medicine, Shandong University Jinan China
| | - Yu Hou
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine Shandong University Jinan Shandong China
| | - Ping Qin
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine Shandong University Jinan Shandong China
| | - Qingshu Zeng
- Department of Hematology The First Affiliated Hospital of Anhui Medical University Hefei China
| | - Wenzheng Yu
- Department of Hematology Binzhou Medical University Hospital Binzhou China
| | - Xinhong Guo
- Department of Hematology The First Affiliated Hospital of Xinjiang Medical University Urumqi China
| | - Jingxia Wang
- Department of Hematology Liaocheng People’s Hospital Liaocheng China
| | - Xiaomin Wang
- Department of Hematology Xinjiang Uiger Municipal People’s Hospital Urumqi China
| | - Guoqiang Liu
- Department of Hematology Shengli Oilfield Central Hospital Dongying China
| | - Xiaoxia Chu
- Department of Hematology Yantai Yuhuangding Hospital Yantai China
| | - Lan Yang
- Department of Hematology Xijing Hospital, Fourth Military Medical University Xi’an China
| | - Ying Feng
- Department of Hematology The Second Affiliated Hospital of Guangzhou Medical University Guangdong China
| | - Fang Zhou
- Department of Hematology Military General Hospital Jinan China
| | - Zhaogang Sun
- Department of Hematology Taian City Central Hospital Taian China
| | - Mei Zhang
- Department of Hematology The First Affiliated Hospital of Xi’an Jiaotong University Xi’an China
| | - Xin Wang
- Department of Hematology Shandong Provincial Hospital Affiliated to Shandong University Jinan China
| | - Zhencheng Wang
- Department of Hematology Zibo Central Hospital Zibo China
| | - Xuehong Ran
- Department of Hematology Weifang People’s Hospital Weifang China
| | - Hongguo Zhao
- Department of Hematology The Affiliated Hospital of Qingdao University Qingdao China
| | - Lei Wang
- Department of Hematology Qingdao Municipal Hospital Qingdao China
| | - Haiyan Zhang
- Department of Hematology Linyi People’s Hospital Linyi China
| | - Kehong Bi
- Department of Hematology Shandong Provincial Qianfoshan Hospital Jinan China
| | - Daqi Li
- Department of Hematology Jinan Central Hospital Jinan China
| | - Chenglu Yuan
- Department of Hematology Qilu Hospital (Qingdao), Shandong University Qingdao China
| | - Ruirong Xu
- Department of Hematology Shandong Provincial Hospital of Traditional Chinese Medicine Jinan China
| | - Yili Wang
- Department of Hematology Weihai Municipal Hospital Weihai China
| | - Yuhong Zhou
- Department of Hematology Zhejiang Provincial Hospital of TCM Hangzhou China
| | - Jun Peng
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine Shandong University Jinan Shandong China
| | - Xin‐guang Liu
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine Shandong University Jinan Shandong China
| | - Ming Hou
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine Shandong University Jinan Shandong China
- Shandong Province Key Laboratory of Hematology/Immunology, Creative Studio of Scientific and Technologic Leading Talents Qilu Hospital, Shandong University Jinan China
| |
Collapse
|
9
|
Sheng Z, Song S, Yu M, Zhu H, Gao A, Gao W, Ran X, Huo D. Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis. Leuk Lymphoma 2020; 61:3432-3439. [PMID: 32862749 DOI: 10.1080/10428194.2020.1811271] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The optimal chemotherapy-free regimens for treatment-naive CLL still remains undefined. We searched relevant published reports. Three trials with 1017 subjects were identified. In the network meta-analysis, acalabrutinib plus obinutuzumab (Aca + Obi) improved PFS than ibrutinib plus obinutuzumab (Ibu + Obi) (HR:0.43, p = .02) and venetoclax plus obinutuzumab (Ven + Obi) (HR:0.30, p < .001) as IRC assessment. Sensitivity analysis of investigator assessment also showed improved PFS with Aca + Obi than Ibu + Obi (HR:0.46, p = .04) and Ven + Obi (HR:0.34, p = .002). Among these first-line treatments (Aca + Obi, Ibu + Obi, Ven + Obi and chlorambucil plus obinutuzumab (Chl + Obi)), Aca + Obi regimen had the highest probability of 99.1% (IRC assessment) or 98.0% (investigator assessment) to reach the longest PFS. The survival advantage with Aca + Obi was not statistically significant, compared to Ibu + Obi (HR:0.51, p = .21) and Ven + Obi (HR:0.38, p = .07). No significant difference was found in AEs analysis. Our data indicated that Aca + Obi seemed to prolong the PFS than Ibu + Obi and Ven + Obi. Considering our limits, prospective clinical trials directly comparing these regimens are warranted.
Collapse
Affiliation(s)
- Zhixin Sheng
- Department of Hematology, Weifang People's Hospital, Weifang, Shandong, China
| | - Shilei Song
- Department of Emergency Neurology, Weifang People's Hospital, Weifang, Shandong, China
| | - Miao Yu
- Department of Stomatology, Weifang People's Hospital, Weifang, Shandong, China
| | - Hongguang Zhu
- Department of Stomatology, Weifang People's Hospital, Weifang, Shandong, China
| | - Anran Gao
- Weifang Medical University, Weifang People's Hospital, Weifang, Shandong, China
| | - Weijie Gao
- Weifang Medical University, Weifang People's Hospital, Weifang, Shandong, China
| | - Xuehong Ran
- Department of Hematology, Weifang People's Hospital, Weifang, Shandong, China
| | - Da Huo
- Department of Oncology, Weifang People's Hospital, Weifang, Shandong, China
| |
Collapse
|
10
|
Wang L, Da H, Li X, Ran X, Wu W, Sheng Z. Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2- Breast cancer: A network meta-analysis of 19 RCTs. Breast J 2020; 26:1862-1866. [PMID: 32037589 DOI: 10.1111/tbj.13780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Revised: 01/15/2020] [Accepted: 01/23/2020] [Indexed: 11/29/2022]
Affiliation(s)
- Lida Wang
- Department of E.N.T, Weifang People's Hospital, Weifang, Shandong, China
| | - Huo Da
- Department of Oncology, Weifang People's Hospital, Weifang, Shandong, China
| | - Xiulian Li
- Department of Maxillofacial Surgery, Weifang People's Hospital, Weifang, Shandong, China
| | - Xuehong Ran
- Department of Hematology, Weifang People's Hospital, Weifang, Shandong, China
| | - Wei Wu
- Department of Stomatology, Weifang People's Hospital, Weifang, China
| | - Zhixin Sheng
- Department of Hematology, Weifang People's Hospital, Weifang, Shandong, China
| |
Collapse
|
11
|
Wang L, Gao S, Li D, Ran X, Sheng Z, Wu W, Yang X. CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2- breast cancer: A meta-analysis of randomized controlled trials. Breast J 2019; 26:1439-1443. [PMID: 31828901 DOI: 10.1111/tbj.13703] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2019] [Revised: 11/12/2019] [Accepted: 11/18/2019] [Indexed: 01/02/2023]
Affiliation(s)
- Liquan Wang
- Department of Breast Surgery, Weifang People's Hospital, Weifang, China
| | - Shuyan Gao
- Department of Hematology, Weifang People's Hospital, Weifang, China
| | - Dianfang Li
- Department of Hematology, Weifang People's Hospital, Weifang, China
| | - Xuehong Ran
- Department of Hematology, Weifang People's Hospital, Weifang, China
| | - Zhixin Sheng
- Department of Hematology, Weifang People's Hospital, Weifang, China
| | - Wei Wu
- Department of Stomatology, Weifang People's Hospital, Weifang, China
| | - Xiaojing Yang
- Department of Hematology, Weifang People's Hospital, Weifang, China
| |
Collapse
|
12
|
Zhou H, Qin P, Liu Q, Yuan C, Hao Y, Zhang H, Wang Z, Ran X, Chu X, Yu W, Wang X, Hou Y, Peng J, Hou M. A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia. Am J Hematol 2019; 94:1374-1381. [PMID: 31591739 DOI: 10.1002/ajh.25646] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 09/24/2019] [Accepted: 09/26/2019] [Indexed: 12/22/2022]
Abstract
We conducted a prospective, multicenter study to evaluate the efficacy and safety of low-dose decitabine in adult patients with refractory immune thrombocytopenia. Adult patients who did not respond to, did not tolerate, or were unwilling to undergo splenectomy, with either a baseline platelet count less than 30 × 109 /L or the presence of bleeding symptoms and further need of ITP-specific treatments, were enrolled. Patients received decitabine at 3.5 mg/m2 intravenously for three consecutive days per cycle, for three cycles with a four-week interval between cycles. All patients were assessed every week during the first 12 weeks and at four-week intervals thereafter. We screened 49 patients for eligibility. Four patients were excluded and 45 received decitabine. At the end of decitabine treatment, complete response was achieved in eight patients (17.78%), and partial response was achieved in 15 patients (33.33%). The median time to initial response was 28 days (range, 14-70 days). Furthermore, seven relapsed patients received decitabine retreatment and all showed platelet response, including one complete response and six partial responses. Sustained response rates at 6, 12 and 18 months were 44.44% (20/45), 31.11% (14/45) and 20.0% (9/45), respectively. For responders, immune thrombocytopenia-related symptoms, fatigue, psychological health, fear, and overall quality of life were significantly improved. Adverse events were observed in 13 (28.89%) patients. No serious adverse events were recorded. In conclusion, low dose decitabine is potentially effective and safe in the management of adults with refractory immune thrombocytopenia. This trial is registered with clinicaltrials.gov identifier: NCT01568333.
Collapse
Affiliation(s)
- Hai Zhou
- Department of Hematology Qilu Hospital, Shandong University Jinan China
| | - Ping Qin
- Department of Hematology Qilu Hospital, Shandong University Jinan China
| | - Qiang Liu
- Department of Hematology Qilu Hospital, Shandong University Jinan China
| | - Chenglu Yuan
- Department of Hematology Qilu Hospital (Qingdao), Shandong University Qingdao China
| | - Yunliang Hao
- Department of Hematology Jining No.1 People's Hospital Jining China
| | - Haiyan Zhang
- Department of Hematology Linyi People's Hospital Linyi China
| | - Zhencheng Wang
- Department of Hematology Zibo Central Hospital Zibo China
| | - Xuehong Ran
- Department of Hematology Weifang People's Hospital Weifang China
| | - Xiaoxia Chu
- Department of Hematology Yantai Yuhuangding Hospital Yantai China
| | - Wenzheng Yu
- Department of Hematology Binzhou Medical University Hospital Binzhou China
| | - Xin Wang
- Department of Hematology Provincial Hospital Affiliated to Shandong University Jinan China
| | - Yu Hou
- Department of Hematology Qilu Hospital, Shandong University Jinan China
| | - Jun Peng
- Department of Hematology Qilu Hospital, Shandong University Jinan China
- Shandong Provincial Key Laboratory of Immunohematology Qilu Hospital, Shandong University Jinan China
- Leading Research Group of Scientific Innovation, Department of Science and Technology of Shandong Province Qilu Hospital, Shandong University Jinan China
| | - Ming Hou
- Department of Hematology Qilu Hospital, Shandong University Jinan China
- Shandong Provincial Key Laboratory of Immunohematology Qilu Hospital, Shandong University Jinan China
- Leading Research Group of Scientific Innovation, Department of Science and Technology of Shandong Province Qilu Hospital, Shandong University Jinan China
| |
Collapse
|
13
|
Xu W, Li D, Sun Y, Ran X, Wang B, Wu W, Sheng Z, Liu L. Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta‐analysis. Eur J Haematol 2019; 103:542-551. [PMID: 31444819 DOI: 10.1111/ejh.13317] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 08/14/2019] [Accepted: 08/16/2019] [Indexed: 11/29/2022]
Affiliation(s)
- Wenjun Xu
- Department of Hematology Weifang People's Hospital Weifang China
| | - DianFang Li
- Department of Hematology Weifang People's Hospital Weifang China
| | - Yanhua Sun
- Department of Hematology Weifang People's Hospital Weifang China
| | - Xuehong Ran
- Department of Hematology Weifang People's Hospital Weifang China
| | - Baohong Wang
- Department of Hematology Weifang People's Hospital Weifang China
| | - Wei Wu
- Department of Stomatology Weifang People's Hospital Weifang China
| | - Zhixin Sheng
- Department of Hematology Weifang People's Hospital Weifang China
| | - Liping Liu
- Department of Hematology Weifang People's Hospital Weifang China
| |
Collapse
|
14
|
Su B, Zhu X, Jiang Y, Wang L, Zhao N, Ran X, Zheng X, Guo H. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Leuk Lymphoma 2018; 60:1381-1388. [PMID: 30516074 DOI: 10.1080/10428194.2018.1543874] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
To evaluate the role of high-dose melphalan plus autologous stem-cell transplantation (ASCT) as consolidation therapy for patients with newly diagnosed multiple myeloma (NDMM) in the era of novel agents, we undertook this meta-analysis. Medline, Embase, the Cochrane controlled trials register, the SCI, ASH, EHA, and ASCO were searched for clinical trials including high-dose chemotherapy plus ASCT for patients with NDMM. Finally, we identified four RCTs of ASCT versus novel agents based consolidations, and 10 single-arm prospective trials of ASCT alone. Pooled analysis indicated that response quality improved further after ASCT in the era of novel agents (≥CR rates of 13% pre-ASCT versus 29% post-ASCT, p = .003). When compared to novel agents containing consolidation regimens, high-dose chemotherapy plus ASCT significantly improved progression-free survival (PFS) (HR =0.56, p < .001). No significant difference in overall survival (OS) was found between them (HR =0.66, p = .22). Of note, subgroup analysis indicated that ASCT could significantly improve OS (HR =0.49, p = .0004) when compared to alkylating agent-based regimens plus lenalidomide consolidation. In summary, response quality and PFS improved further over ASCT in the era of novel agents. ASCT could improve survival than alkylating agent-based regimens plus lenalidomide consolidations for patients with NDMM.
Collapse
Affiliation(s)
- Baohua Su
- a Department of Hematology , Weifang People's Hospital , Weifang , China
| | - Xu Zhu
- a Department of Hematology , Weifang People's Hospital , Weifang , China
| | - Yina Jiang
- b Department of Ultrasonography , Weifang People's Hospital , Weifang , China
| | - Lida Wang
- c E.N.T. Department , Weifang People's Hospital , Weifang , China
| | - Ningning Zhao
- a Department of Hematology , Weifang People's Hospital , Weifang , China
| | - Xuehong Ran
- a Department of Hematology , Weifang People's Hospital , Weifang , China
| | - Xiaobin Zheng
- d Department of Respiration , The Fifth Affiliated Hospital Sun Yat-sen University , Zuhai , China
| | - Hui Guo
- e Department of Neurosurgery , Weifang People's Hospital , Weifang , China
| |
Collapse
|
15
|
Zou Y, Ma X, Yu H, Hu C, Fan L, Ran X. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. Oncotarget 2017; 8:39805-39817. [PMID: 27458170 PMCID: PMC5503655 DOI: 10.18632/oncotarget.10768] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2016] [Accepted: 07/10/2016] [Indexed: 12/15/2022] Open
Abstract
PURPOSE The use of carfilzomib/pomalidomide single-agent or in combination with other agents in patients with refractory/relapsed multiple myeloma (RRMM) was not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the efficacy and safety of carfilzomib (CFZ) and pomalidomide (POM). RESULTS Based on our research criteria, we identified 37 prospective studies that evaluated 1160 patients. Analysis of subgroup differences between carfilzomib single-agent and CFZ/DEX dual combination showed significantly(P < 0.001, I2 = 96.3%), suggesting the overall response rate (ORR) of 66% attained from CFZ/DEX dual combination seemed to be higher than that of 28% from carfilzomib single-agent. And, the same trend favoring CFZ/DEX dual combination was found in ≥VGPR and CBR analysis. The ORR of 31% attained from POM/DEX dual combination was superior to that of 19% from pomalidomide single-agent(P < 0.001, I2 = 94.4%). And, the same trend favoring POM/DEX dual combination was found in ≥VGPR and CBR analysis. However, the ORR of 83% attained from POM/BOR/DEX triplet combination was superior to that of 31% from POM/DEX dual combination(P < 0.001, I2 = 99.1%). And, the same trend favoring POM/BOR/DEX triplet combination was found in ≥VGPR analysis. METHODS We searched published reports including carfilzomib and (or) pomalidomide therapy for RRMM who had received bortezomib and (or) lenalidomide. CONCLUSION Pomalidomide/Carfilzomib plus dexamethasone seemed to attain a superior response rate compared with pomalidomide/carfilzomib single-agent. Furthermore, the combination of pomalidomide, bortezomib and dexamethasone resulted in a much higher response rate compared with pomalidomide plus dexamethasone regimen. These results needed more validation in future trials.
Collapse
Affiliation(s)
- Yandun Zou
- Internal Medicine, Guang Dong Women and Children Hospital, Guang Zhou, China
| | - Xiaoyan Ma
- Department of I.C.U, Weifang People's Hospital, Weifang, China
| | - Haiying Yu
- Department of Pediatrics, Weifang People's Hospital, Weifang, China
| | - Chunling Hu
- Internal Medicine, Guang Dong Women and Children Hospital, Guang Zhou, China
| | - Limei Fan
- Internal Medicine, Guang Dong Women and Children Hospital, Guang Zhou, China
| | - Xuehong Ran
- Department of Hematology, Weifang People's Hospital, Weifang, China
| |
Collapse
|
16
|
Wu X, Wang L, Sun L, Li T, Ran X. Analysis of clinical effects and mechanism of recombinant human interleukin-11 with glucocorticoids for treatment of idiopathic thrombocytopenic purpura. Exp Ther Med 2016; 13:519-522. [PMID: 28352325 PMCID: PMC5347441 DOI: 10.3892/etm.2016.3989] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2016] [Accepted: 12/19/2016] [Indexed: 12/22/2022] Open
Abstract
The aim of the present study was to evaluate the effectiveness and safety of recombinant human interleukin-11 (IL-11) with glucocorticoids for treatment of adult idiopathic thrombocytopenic purpura (ITP) and the regulatory effect on immune mechanisms. A total of 80 patients with initial diagnosis of ITP admitted to our hospital were selected. Patients were randomly divided into the control group and observation group, with 40 cases each. The control group received glucocorticoids treatment, and the observation group received IL-11 and glucocorticoids. The treatment effects were compared. The total effective rate and effective degree of the observation group was higher than in the control group and the difference was statistically significant (P<0.05); comparing the incidence of complications of the two groups, there was no statistical difference (P>0.05). In the observation group, onset time was reduced, platelet recovery level increased and platelet antibody positive rate decreased, and the differences were statistically significant (P<0.05). The total treatment course was shorter and recurrence rate was lower in the observation group compared with the control group, and the differences were statistically significant (P<0.05). The percentage of CD4+CD25+ regulatory T cells decreased in the two groups after treatment, and was more pronounced in the observation group. The difference was statistically significant (P<0.05). In conclusion, IL-11 with glucocorticoids for the treatment of adult ITP is safe and effective, and may be associated with decreased percentage of CD4+CD25+ regulatory T cells.
Collapse
Affiliation(s)
- Xifeng Wu
- Department of Hematology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China
| | - Lijuan Wang
- Department of Hematology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China
| | - Lin Sun
- Department of Hematology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China
| | - Tantan Li
- Department of Hematology, Laiwu City People's Hospital, Laiwu, Shandong 271100, P.R. China
| | - Xuehong Ran
- Department of Hematology, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
| |
Collapse
|
17
|
Ren CA, Li YX, Cui JY, Sheng ZX, Ran XH, Wang BH, Zhang MH. Efficacy of glycyrrhizin combined with cyclosporine in the treatment of non-severe aplastic anemia. Chin Med J (Engl) 2013; 126:2083-2086. [PMID: 23769562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023] Open
Abstract
BACKGROUND Cyclosporine A (CsA) has been widely used in the treatment of aplastic anemia (AA), but the application of CsA was limited in patients who had liver diseases or abnormal liver function due to its liver toxicity. Glycyrrhizin has long been used in China in the treatment of various liver diseases to lower transaminases. In this study, we observed the efficacy and safety of glycyrrhizic acid combined with CsA in the treatment of newly diagnosed patients with non-severe AA (NSAA). METHODS A total number of 76 patients with newly diagnosed NSAA were enrolled into the study at our hospital between July 2005 and June 2010. The patients were divided randomly into two groups: the glycyrrhizin-treatment group (group A) and the control group (group B) with 38 patients in each group. All patients received 3 - 5 mg×kg(-1)×d(-1) CsA for at least 4 months and were treated either with or without glycyrrhizin for 4 months. RESULTS sixty-eight patients were eligible for evaluation. In the control group, 9.09% patients (n = 3) achieved a complete response while 51.52% (n = 17) attained a partial response. The overall response rate was 60.61% (n = 20). The remaining 13 patients (39.39%) did not have any response. In the glycyrrhizin-treatment group, complete response rate was 20% (n = 7) and partial response rate was 62.86% (n = 22). The overall response rate was 82.86% (n = 29) and the non-response rate was 17.14% (n = 6). Response rate was significantly increased with the addition of glycyrrhizin to CsA compared with CsA alone (P < 0.05). CONCLUSION The combination of glycyrrhizin and cyclosporine regimen was an effective treatment for NSAA in terms of improvement of response rate, reduction in CsA-related liver injury, and attenuation of severity of nausea and other adverse events in the treatment of patients with NSAA.
Collapse
Affiliation(s)
- Cui-ai Ren
- Department of Hematology, Weifang People's Hospital, Weifang, Shandong, China.
| | | | | | | | | | | | | |
Collapse
|
18
|
Sun YH, Sun YL, Ran XH, Cui JY, Zhang HL, Chen ZX. [The influence of CD44 on the adhesive, migratory and infiltrative abilities of leukemia cells]. Zhonghua Xue Ye Xue Za Zhi 2013; 34:60-63. [PMID: 23597468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
OBJECTIVE To investigate the expression of CD44 in leukemia cell lines and its role in adhesion, migration and infiltration of leukemia cells. METHODS The expression levels of CD44 in four leukemia cell lines SHI-1, THP-1, NB4 and K562 were assayed by reverse transcription-polymerase chain reaction (RT-PCR) and Western blot when they were in logarithmic phase. And these cell lines were divided into control group (treated with same species and isotype IgG) and experimental group (treated with anti-CD44 mono-clonal antibody). The assays of cell-cell adhesion to endothelial cells line ECV304, migration through the artificial matrix membrane and infiltration through the Matrigel were performed. RESULTS The relative expression ratios of CD44 to GAPDH in SHI-1, THP-1, NB4 cells were 0.0731 ± 0.0072, 0.0827 ± 0.0151 and 0.1473 ± 0.0365, respectively, which were significantly higher than that in K562 cells (0.0002 ± 0.0000, P < 0.01). Cell-cell adhesion assay showed that the adhesion rates of SHI-1, THP-1 and NB4 cells in the experimental group decreased to 72.78%, 64.09% and 57.42%, respectively, and were lower than those of the control groups, while that of K562 cells in the experimental group was 106.16%. Migration assay showed that the transmembrane rates of SHI-1,THP-1 and NB4 cells were 55%, 29% and 25% in the control group, respectively, and decreased to 32%, 18% and 12% in the experimental group, respectively, while those of K562 cells in both control group and experimental group remained 2%. The infiltration rates of SHI-1, THP-1 and NB4 cells decreased from 24%, 15% and 13% in the control group to 12%, 8% and 4% in the experimental group, respectively, while K562 cells in both groups could not pass through the Matrigel. CONCLUSION CD44 antigen might play an important role in the adhesion, migration and infiltration of leukemia cells and be involved in the extra-medullary infiltration of leukemia cells.
Collapse
Affiliation(s)
- Yan-hua Sun
- Jiangsu Institute of Hematology, Suzhou, China
| | | | | | | | | | | |
Collapse
|
19
|
Wang L, Ran X, Wang B, Sheng Z, Liu L. Novel agents-based regimens as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Hematol Oncol 2011; 30:57-61. [PMID: 21809367 DOI: 10.1002/hon.1007] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2011] [Revised: 05/18/2011] [Accepted: 05/26/2011] [Indexed: 11/09/2022]
Abstract
To investigate the effect of novel agents like bortezomib, lenalidomide and thalidomide as part of induction treatment prior to autologous stem-cell transplantation (ASCT) for previously untreated patients with multiple myeloma, we performed a meta-analysis of randomized controlled trials (RCTs). Medline, Embase, the Cochrane controlled trials register and the Science Citation Index were searched for RCTs of novel agents as part of induction therapy before ASCT. Three RCTs of bortezomib, two RCTs of thalidomide and no RCT of lenalidomide were identified, covering a total of 2,316 subjects. Due to different mechanisms of action, we performed a subgroup analysis by type of agent (thalidomide or bortezomib). The weighted risk ratios of a complete response (CR) were 4.25 [95% CI: 2.44-7.41] (p < 0.001) for bortezomib and 1.66 [95% CI: 1.15-2.38] (p = 0.007) for thalidomide, respectively. The summary hazard ratios for progression-free survival (PFS) were 0.73 [95% CI: 0.59-0.89] (p = 0.002) for bortezomib and 0.68 [95% CI: 0.59-0.79] (p < 0.001) for thalidomide, respectively. The corresponding ratios for overall survival (OS) were 0.87 [95% CI: 0.64-1.18] (p = 0.37) and 0.88 [95% CI: 0.73-1.05] (p = 0.14), respectively. Additionally, there was a statistically significant heterogeneity between subgroups (thalidomide and bortezomib) for CR (p = 0.005) but nonsignificant for PFS (p = 0.64) and OS (p = 0.97). In conclusion, our analysis showed novel agents as induction treatment prior to ASCT improved CR and PFS but not OS.
Collapse
Affiliation(s)
- Lida Wang
- E.N.T. department, Weifang People's Hospital of Weifang Medical University, Weifang, China
| | | | | | | | | |
Collapse
|